Search

Following the disruptive epidemics throughout the Indian Ocean, Southeast Asia and the Americas, efforts have been deployed to develop an effective vaccine against chikungunya virus (CHIKV). The continuous threat of CHIKV (re-)emergence and the huge public health and economic impact of the epidemics, makes the development of a safe and effective vaccine a priority. Several platforms have been used to develop candidate vaccines, but there is no consensus about how to translate results from preclinical models to predict efficacy in humans. This paper outlines a concept of what constitutes an effective vaccine against CHIKV, which may be applied to other viral vaccines as well. Defining endpoints for an effective vaccine is dependent on a proper understanding of the pathogenesis and immune response triggered during infection. The preclinical model adopted to evaluate experimental vaccines is imperative for the translation of preclinical efficacy data to humans. Several CHIKV animal models exist; however, not all provide suitable endpoints for measuring vaccine efficacy. This review summarizes the current knowledge related to CHIKV pathogenesis and the correlates of protection. We then define what would constitute an effective CHIKV vaccine in humans using four key endpoints, namely: (i) prevention of chronic disease, (ii) prevention of acute disease, (iii) prevention of transmission to mosquitoes, and (iv) complete prevention of infection. Lastly, we address some of the gaps that prevent translation of immunogenicity and efficacy findings from preclinical models to humans, and we propose to use the combination of virus–cytokine–ferritin levels as a read-out for measuring vaccine-induced protection.

This is the first study reporting whole genome sequences of two CHIKV strains (KJ679577 and KJ679578) isolated from Eastern Indian patients sera during 2010–2011 outbreak, both of which were of ECSA genotype, but from different subgroups: Indian Ocean outbreak and ECSA subtypes. Furthermore, viral sequences were analyzed using different in-silico approaches to identify potential genetic variations that might have functional implications on various aspects of virus replication, viral protein functionality, immunogenicity and transmission. Epitope prediction analysis revealed 70.9% increase in number of MHC Class-II interacting epitopes of KJ679578 and 25–28% increase in Class-I interacting epitopes of KJ679577 and KJ679578 compared to that of EF027141 (CHIKV of Asian genotype circulating in India during 1973, after which CHIKV infection disappeared from India for three decades). CHIKV peptides DLAKLAFKRSSKYDLECAQIPVHMKSDA and KVVLCGDPKQCGFFNMMQMKYNYNHNI were predicted to interact with maximum number of HLA Class-I (68 and 76.5%, respectively) and Class-II (47 and 100%, respectively) alleles present within Indian population with allele frequency of > 0.1 and were also recognized as predicted B-cell epitopes with BCPred score between 0.766 and 0.961 and with antigenicity ranging from 0.52 to 1.69; thus these peptides might be used to induce T- and B-cell-mediated immunity against CHIKV. Thus, the present study might help to bridge the gap between virus microevolution and its implication in host immunity by taking into account viral genetic and conformational changes. Predicted epitopes might be used as promising targets for peptide-based vaccine development and rapid diagnostics against CHIKV infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13205-018-1339-3) contains supplementary material, which is available to authorized users.

Chikungunya virus (CHIKV) infection leads to activation of innate immune response by triggering Toll-like receptor (TLR) pathways resulting in elevated cytokines and type-I interferon levels. Genetic variations of these genes may influence human CHIKV-susceptibility and disease progression. Present study aimed to identify role of TLR polymorphisms in CHIKV-susceptibility and their association with cytokines and clinical symptoms. This is the first study illustrating certain genotypes of TLR-7 and TLR-8 SNPs viz. CT(p = 0.002)]; rs3853839[GC(p < 0.001), CC(p = 0.039)] and rs3764879[GC(p < 0.001)] were considerably associated with CHIKV susceptibility. Increased risk of CHIKV infection among male patients with CC-genotype (rs179010) (p = 0.028) and female patients with GT-genotype (rs5741880) (p = 0.019) was observed. Significant higher IFN-α (P = 0.002) levels among chikungunya TNF-α (P = 0.034) patients was reported. Chikungunya patients with rs179010-CC genotype showed significantly high IFN-α level(p = 0.003). Thus, these TLR variants might act as potential prognostic biomarkers for predicting CHIKV susceptibility among uninfected individuals.

During last three decades, dengue (DF), an arthropod-borne viral disease is increasingly prevalent worldwide including India, resulting in serious public health problems.This study was carried out during 2012-2013 to evaluate the association of WHO-classified dengue disease symptoms with viral load (VL) and serum IFN-gamma levels in dengue patients from India.Blood samples were collected from dengue symptomatic febrile patients (n=127). DEN-VL was determined by quantitative real-time RT-PCR using RNA, extracted from plasma and anti-DENV-IgM was detected by ELISA. Serum IFN-gamma level was detected by ELISA among DENV infected and age-matched control individuals. Association between DEN-VL and IFN-gamma level in patient's sera with WHO-classified disease symptoms was statistically analyzed.DENV RNA and anti-DENV-IgM was detected among 94% (n=73) and 36% (n=28) of dengue infected patients (n=78) respectively. Fever, nausea, rash, achespains, leucopenia and persistent vomiting were significantly correlated with DENV infection (P-value0.05). Only patients with high-VL exhibited leucopenia, persistent vomiting, abdominal pain and clinical fluid accumulation, which were warning signs of dengue infection according to revised WHO-criteria (P-value0.05). Clinical symptoms of DENV infected patients, viz. leucopenia, abdominal pain and persistent vomiting were significantly correlated to each other (P-value0.05). Increased serum IFN-gamma level was detected among dengue patients compared to control individuals. DEN-VL and symptoms like nausea, leucopenia, persistent vomiting and abdominal pain were significantly negatively correlated with serum IFN-gamma level (P-value0.05).Serum IFN-gamma level and dengue viremia among acute stage patients might be used as early prognostic marker for disease severity prediction.

After a gap of three decades, from 2005 onwards, a series of Chikungunya virus (CHIKV) outbreaks occurred worldwide. This study was performed to detect CHIKV infection, its genotype among symptomatic Eastern Indian patients and to analyze any association between the presence of CHIKV genome in patient body with appearance of disease symptoms (n = 199). Plasma-extracted viral RNA was reverse transcribed to cDNA and PCR-amplified followed by agarose gel electrophoresis. Viral load among CHIKV-positive patients was determined by real time RT-PCR. CHIKV-IgM in sera was detected by ELISA. Sequencing and phylogenetic analysis of plasma-extracted PCR products was done. CHIKV genome and IgM were detected among 65.3% (n = 130) and 41.2% (n = 82) patients respectively. Joint swelling was significantly associated with CHIKV infection (P-value: 0.0003). CHIKV PCR positive patients were grouped in two categories: Group-I: viral load

Pathogenic Klebsiella pneumoniae, resistant to beta-lactam and quinolone drugs, is widely recognized as important bacteria causing array of diseases. The resistance property is obtained by acquisition of plasmid encoded blaTEM, blaSHV, blaCTX-M, QNRA, QNRB and QNRS genes. The aim of this study was to document the prevalence and association of these resistant genes in K. pneumoniae infecting patients in India. Approximately 97 and 76.7 % of the 73 K. pneumoniae isolates showed resistance towards beta-lactam and quinolone drugs respectively. Bla genes were detected in 74 % of K. pneumoniae isolates; with prevalence in the following order: blaTEM > blaSHV > blaCTXM. QNR genes were detected in 67 % samples. Chi-square analysis revealed significant association between presence of bla and qnr genes in our study (P value = 0.000125). Sequence analysis of some blaTEM, blaSHV, blaCTX-M and QNRB PCR products revealed presence of blaTEM1 (GenBank accession: JN193522), blaTEM116 (JN193523 and JN193524), blaSHV11, blaCTXM72 variants (JF523199) and QNRB1 (JN193526 and JN193527) in our samples.